加载中
NASDAQHealthcareMedical - Devices
最新数据
US$0.1303
−US$0.0017 · -1.29%
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
常规交易时段
US$0.1303
−US$0.0017 · -1.29%
盘中时间采用ET。市场数据可能有所延迟。
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
日内区间
当前US$0.1303
52周区间
当前US$0.1303
盘中时间采用ET。市场数据可能有所延迟。
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
日内区间
当前US$0.1303
52周区间
当前US$0.1303
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 26.9万 USD | 30万 USD | 18.9万 USD | 27万 USD |
| 销货成本 | 68.4万 USD | 193.7万 USD | 130.6万 USD | 87.5万 USD | 115.8万 USD |
| 毛利 | −68.4万 USD | −166.8万 USD | −100.6万 USD | −68.6万 USD | −88.8万 USD |
| 研究与开发 | 1063.9万 USD | 463.4万 USD | 1539.9万 USD | 1785.5万 USD | 1535.5万 USD |
| 销售、一般及管理费用 | 1056.7万 USD | 697.6万 USD | 1153.7万 USD | 537.2万 USD | 440.2万 USD |
| 营业费用 | 2120.6万 USD | 6081.2万 USD | 2693.6万 USD | 2322.7万 USD | 1975.7万 USD |
| 利息收入 | 47.7万 USD | 42.3万 USD | 3000 USD | 3.9万 USD | 3000 USD |
| 利息支出 | 290.6万 USD | −110.2万 USD | 165.9万 USD | 13.7万 USD | — |
| 折旧和摊销 | 97万 USD | 138.6万 USD | 53.2万 USD | 49.5万 USD | 33.6万 USD |
| 营业利润 | −2189万 USD | −6248万 USD | −2794.2万 USD | −2391.3万 USD | −2064.5万 USD |
| 净利润 | −2508.4万 USD | −5376.3万 USD | −3814.6万 USD | −2367.3万 USD | −1993.8万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$3.00
上涨空间 2202.38%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
